{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:34:55Z","timestamp":1780054495587,"version":"3.54.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12282-022-01424-3","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T11:37:48Z","timestamp":1671709068000},"page":"309-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-2763","authenticated-orcid":false,"given":"Tomoe","family":"Taji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-3534","authenticated-orcid":false,"given":"Nina","family":"Odan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7982-5213","authenticated-orcid":false,"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5427-9287","authenticated-orcid":false,"given":"Mako","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-2597","authenticated-orcid":false,"given":"Ai","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4980-964X","authenticated-orcid":false,"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"11","key":"1424_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329\u201333. https:\/\/doi.org\/10.1200\/JCO.2006.09.1066.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1424_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13053-016-0048-3","volume":"14","author":"DG Evans","year":"2016","unstructured":"Evans DG, Harkness EF, Howell A, et al. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hered Cancer Clin Pract. 2016;14(1):1\u20138. https:\/\/doi.org\/10.1186\/s13053-016-0048-3.","journal-title":"Hered Cancer Clin Pract"},{"issue":"4","key":"1424_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12282-015-0619-6","volume":"22","author":"L Xu","year":"2015","unstructured":"Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer. 2015;22(4):327\u201334. https:\/\/doi.org\/10.1007\/s12282-015-0619-6.","journal-title":"Breast Cancer"},{"issue":"33","key":"1424_CR4","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","volume":"31","author":"PG Moorman","year":"2013","unstructured":"Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188\u201398. https:\/\/doi.org\/10.1200\/JCO.2013.48.9021.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1424_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.breastdis.2011.06.001","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967\u201375. https:\/\/doi.org\/10.1016\/j.breastdis.2011.06.001.","journal-title":"JAMA"},{"issue":"4","key":"1424_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/gim.2017.118","volume":"20","author":"Z Chen","year":"2018","unstructured":"Chen Z, Kolor K, Grosse SD, et al. Trends in utilization and costs of BRCA testing among women aged 18\u201364 years in the United States, 2003\u20132014. Genet Med. 2018;20(4):428\u201334. https:\/\/doi.org\/10.1038\/gim.2017.118.","journal-title":"Genet Med"},{"issue":"1","key":"1424_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000441714","volume":"19","author":"S Nakamura","year":"2016","unstructured":"Nakamura S, Kwong A, Kim SW, et al. Current status of the management of hereditary breast and ovarian cancer in asia: first report by the asian BRCA consortium. Public Health Genomics. 2016;19(1):53\u201360. https:\/\/doi.org\/10.1159\/000441714.","journal-title":"Public Health Genomics"},{"key":"1424_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-022-01342-4","author":"S Hayashi","year":"2022","unstructured":"Hayashi S, Kubo M, Kaneshiro K, et al. Genetic medicine is accelerating in Japan. Breast Cancer. 2022. https:\/\/doi.org\/10.1007\/s12282-022-01342-4.","journal-title":"Breast Cancer"},{"issue":"4","key":"1424_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12282-015-0618-7","volume":"23","author":"H Nakagomi","year":"2016","unstructured":"Nakagomi H, Sakamoto I, Hirotsu Y, et al. Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses. Breast Cancer. 2016;23(4):649\u201353. https:\/\/doi.org\/10.1007\/s12282-015-0618-7.","journal-title":"Breast Cancer"},{"key":"1424_CR10","volume-title":"TNM Classification of Malignant Tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. Hoboken: John Wiley & Sons; 2017."},{"issue":"4","key":"1424_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10897-016-0064-5","volume":"26","author":"S Hayden","year":"2017","unstructured":"Hayden S, Mange S, Duquette D, Petrucelli N, Raymond VM. Large, Prospective analysis of the reasons patients do not pursue brca genetic testing following genetic counseling. J Genet Couns. 2017;26(4):859\u201365. https:\/\/doi.org\/10.1007\/s10897-016-0064-5.","journal-title":"J Genet Couns"},{"issue":"3","key":"1424_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10897-010-9282-4","volume":"19","author":"KM Sussner","year":"2010","unstructured":"Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB. Interest and beliefs about BRCA genetic counseling among at-risk latinas in New York City. J Genet Couns. 2010;19(3):255\u201368. https:\/\/doi.org\/10.1007\/s10897-010-9282-4.","journal-title":"J Genet Couns"},{"issue":"1","key":"1424_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-012-2021-9","volume":"134","author":"F Fostira","year":"2012","unstructured":"Fostira F, Tsitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: Implications for genetic screening selection criteria: a hellenic cooperative oncology group study. Breast Cancer Res Treat. 2012;134(1):353\u201362. https:\/\/doi.org\/10.1007\/s10549-012-2021-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1424_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s10038-020-00849-y","volume":"66","author":"M Okano","year":"2021","unstructured":"Okano M, Nomizu T, Tachibana K, et al. The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. J Hum Genet. 2021;66(3):307\u201314. https:\/\/doi.org\/10.1038\/s10038-020-00849-y.","journal-title":"J Hum Genet"},{"issue":"13","key":"1424_CR15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/hmg\/10.13.1421","volume":"10","author":"M Sekine","year":"2001","unstructured":"Sekine M, Nagata H, Tsuji S, et al. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. Hum Mol Genet. 2001;10(13):1421\u20139. https:\/\/doi.org\/10.1093\/hmg\/10.13.1421.","journal-title":"Hum Mol Genet"},{"issue":"June","key":"1424_CR16","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.3747\/co.25.3954","volume":"25","author":"JM Lebert","year":"2018","unstructured":"Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol. 2018;25(June):S142\u201350. https:\/\/doi.org\/10.3747\/co.25.3954.","journal-title":"Curr Oncol"},{"issue":"6","key":"1424_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/nejmoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/nejmoa1706450.","journal-title":"N Engl J Med"},{"key":"1424_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2105215","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/nejmoa2105215.","journal-title":"N Engl J Med"},{"issue":"3","key":"1424_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s40615-018-00556-7","volume":"6","author":"CD Williams","year":"2020","unstructured":"Williams CD, Bullard AJ, Goldstein K. Racial\/Ethnic disparities in brca counseling and testing\u202f: a narrative review. J Racial Ethnic Health Dispar. 2020;6(3):570\u201383.","journal-title":"J. Racial Ethnic Health Dispar."},{"issue":"10","key":"1424_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1177\/0003134820964444","volume":"86","author":"MK Srour","year":"2020","unstructured":"Srour MK, Amersi F, Mirocha J, Giuliano AE, Chung A. Male breast cancer\u202f: 13-year single institution experience. Am Surg. 2020;86(10):1345\u201350. https:\/\/doi.org\/10.1177\/0003134820964444.","journal-title":"Am Surg"},{"issue":"5","key":"1424_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12282-013-0503-1","volume":"22","author":"S Nakamura","year":"2015","unstructured":"Nakamura S, Takahashi M, Tozaki M, et al. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer. 2015;22(5):462\u20138. https:\/\/doi.org\/10.1007\/s12282-013-0503-1.","journal-title":"Breast Cancer"},{"issue":"15","key":"1424_CR22","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.20.02785","volume":"39","author":"AW Kurian","year":"2021","unstructured":"Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012\u20132019. J Clin Oncol. 2021;39(15):1631\u201340. https:\/\/doi.org\/10.1200\/JCO.20.02785.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-022-01424-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T16:23:39Z","timestamp":1677169419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-022-01424-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s12282-022-01424-3","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this work have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}